Skip to main content
Erschienen in: Annals of Hematology 1/2005

01.01.2005 | Original Article

Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000

verfasst von: Mar Ortega, Montserrat Rovira, Manel Almela, Francesc Marco, Jorge Puig de la Bellacasa, José Antonio Martínez, Enric Carreras, Josep Mensa

Erschienen in: Annals of Hematology | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

To examine shifts in the etiology, incidence, evolution, susceptibility, and patient mortality of bacterial and fungal bloodstream isolates (BSIs) from hematopoietic stem cell transplantation (HSCT) recipients, we reviewed the BSIs of 796 patients who underwent an HSCT in our institution during a 10-year period. Four hundred eighty-nine episodes of bacterial and fungal BSI were detected in 330 patients (41%). Three hundred ten isolates (63%) were gram-positive bacteria, 142 (29%) were gram-negative, and 18 and 19 isolates were different species of anaerobic organism and Candida spp. (both 4%). Coagulase-negative staphylococci (CoNS), with 210 isolates, were the organism most frequently isolated in each year of study and during the three phases of immune recovery after HSCT. The ratio of gram-positive to gram-negative has declined from 3.3 (1991–1992) to 1.8 (1999–2000). Crude mortality occurred in 47 cases of 489 BSI episodes (10%). Mortality according to groups was gram-negative, 7%; gram-positive, 9%; and anaerobic bacteria, 11%. Candida spp. was the group that accounted for the highest crude mortality, with 42%. Gram-positive microorganisms were isolated more often than gram-negative organisms, but the trend is reversing. CoNS were the leading pathogen during the 10 years of study and during the three phases of immune recovery after HSCT. Crude mortality of HSCT patients with BSI was low except for infections caused by Candida spp.
Literatur
1.
Zurück zum Zitat Awada A, van der Auwera P, Meunier F, Daneau D, Klastersky J (1992) Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis 15:33–48PubMed Awada A, van der Auwera P, Meunier F, Daneau D, Klastersky J (1992) Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis 15:33–48PubMed
2.
Zurück zum Zitat Bochud PY, Calandra T, Francioli P (1994) Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 97:256–264CrossRefPubMed Bochud PY, Calandra T, Francioli P (1994) Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 97:256–264CrossRefPubMed
3.
Zurück zum Zitat Collin BA, Leather HL, Wingard JR, Ramphal R (2001) Evolution, incidence and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 33:947–953CrossRefPubMed Collin BA, Leather HL, Wingard JR, Ramphal R (2001) Evolution, incidence and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 33:947–953CrossRefPubMed
4.
Zurück zum Zitat Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330:1240CrossRefPubMed Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330:1240CrossRefPubMed
5.
Zurück zum Zitat Cometta A, Zinner S, Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment Cancer. Antimicrob Agents Chemother 39:445–452PubMed Cometta A, Zinner S, Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment Cancer. Antimicrob Agents Chemother 39:445–452PubMed
6.
Zurück zum Zitat Durand-Gasselin B, Leclercq R, Girard-Pipau F, Deharvengt MC, Rochant H, Astier A, Duval J, Cordonnier C (1995) Evolution of bacterial susceptibility to antibiotics during a six-year period in a haematology unit. J Hosp Infect 29:19–33CrossRefPubMed Durand-Gasselin B, Leclercq R, Girard-Pipau F, Deharvengt MC, Rochant H, Astier A, Duval J, Cordonnier C (1995) Evolution of bacterial susceptibility to antibiotics during a six-year period in a haematology unit. J Hosp Infect 29:19–33CrossRefPubMed
7.
Zurück zum Zitat Elting LS, Bodey GP, Keefe BH (1992) Septicemia and shock syndrome due to viridans streptococci: a case control study of predisposing factors. Clin Infect Dis 14:1201–1207 Elting LS, Bodey GP, Keefe BH (1992) Septicemia and shock syndrome due to viridans streptococci: a case control study of predisposing factors. Clin Infect Dis 14:1201–1207
8.
Zurück zum Zitat Engelhard D, Elishoov H, Strauss N, Naparstek E, Nagler A, Simhon A, Raveh D, Slavin S, Or R (1996) Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter: a 5-year prospective study. Transplantation 61:430–434CrossRefPubMed Engelhard D, Elishoov H, Strauss N, Naparstek E, Nagler A, Simhon A, Raveh D, Slavin S, Or R (1996) Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter: a 5-year prospective study. Transplantation 61:430–434CrossRefPubMed
9.
Zurück zum Zitat The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment Cancer (1990) Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 26:569–574 The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment Cancer (1990) Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 26:569–574
10.
Zurück zum Zitat Klastersky J (1986) Concept of empiric therapy with antibiotic combinations indications and limits. Am J Med 80:2–12 Klastersky J (1986) Concept of empiric therapy with antibiotic combinations indications and limits. Am J Med 80:2–12
11.
Zurück zum Zitat Klastersky J (1998) Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 41[Suppl D]:13–24CrossRef Klastersky J (1998) Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 41[Suppl D]:13–24CrossRef
12.
Zurück zum Zitat Koc Y, Snydman DR, Schenkein DS, Miller KB (1998) Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Bone Marrow Transplant 22:207–209CrossRefPubMed Koc Y, Snydman DR, Schenkein DS, Miller KB (1998) Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Bone Marrow Transplant 22:207–209CrossRefPubMed
13.
Zurück zum Zitat Koll BS, Brown AE (1993) The changing epidemiology of infections at cancer hospitals. Clin Infect Dis 17[Suppl 2]:322–328 Koll BS, Brown AE (1993) The changing epidemiology of infections at cancer hospitals. Clin Infect Dis 17[Suppl 2]:322–328
14.
Zurück zum Zitat Kruger W, Russmann B, Kroger N, Salomon C, Ekopf N, Elsner HA, Kaulfers PM, Mack D, Fuchs N, Durken M, Kabisch H, Erttmann R, Zander AR (1999) Early infections in patients undergoing bone marrow or blood stem cell transplantation: a 7-year single-centre investigation of 409 cases. Bone Marrow Transplant 23:589–597CrossRefPubMed Kruger W, Russmann B, Kroger N, Salomon C, Ekopf N, Elsner HA, Kaulfers PM, Mack D, Fuchs N, Durken M, Kabisch H, Erttmann R, Zander AR (1999) Early infections in patients undergoing bone marrow or blood stem cell transplantation: a 7-year single-centre investigation of 409 cases. Bone Marrow Transplant 23:589–597CrossRefPubMed
15.
Zurück zum Zitat McClelland RS, Fowler VG Jr, Sanders LL, Gottlieb G, Kong LK, Sexton DJ, Schmader K, Lanclos KD, Corey R (1999) Staphylococcus aureus bacteremia among elderly vs. younger adult patients: comparison of clinical features and mortality. Arch Intern Med 159:1244–1247CrossRefPubMed McClelland RS, Fowler VG Jr, Sanders LL, Gottlieb G, Kong LK, Sexton DJ, Schmader K, Lanclos KD, Corey R (1999) Staphylococcus aureus bacteremia among elderly vs. younger adult patients: comparison of clinical features and mortality. Arch Intern Med 159:1244–1247CrossRefPubMed
16.
Zurück zum Zitat Murray P, Baron E, Pfaller M, Tenover F, Yolken R (eds) (1999) Manual of clinical microbiology, 7th edn. ASM, Washington Murray P, Baron E, Pfaller M, Tenover F, Yolken R (eds) (1999) Manual of clinical microbiology, 7th edn. ASM, Washington
17.
Zurück zum Zitat National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing, 12th informational supplement. Document M100-S12. National Committee for Clinical Laboratory Standards, Wayne National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing, 12th informational supplement. Document M100-S12. National Committee for Clinical Laboratory Standards, Wayne
18.
Zurück zum Zitat Rolston KVI, Raad R, Whimbley (1997) The changing spectrum of bacterial infections in febrile neutropenic patients. In: Klatersky JA (ed) Febrile neutropenia. Springer, New York Berlin Heidelberg, pp 53–56 Rolston KVI, Raad R, Whimbley (1997) The changing spectrum of bacterial infections in febrile neutropenic patients. In: Klatersky JA (ed) Febrile neutropenia. Springer, New York Berlin Heidelberg, pp 53–56
19.
Zurück zum Zitat Rubio M, Romero J, Corral O, Roca V, Picazo JJ (1999) Bacteremia by Staphylococcus aureus: analysis of 311 episodes. Enferm Infecc Microbiol Clin 17:56–64PubMed Rubio M, Romero J, Corral O, Roca V, Picazo JJ (1999) Bacteremia by Staphylococcus aureus: analysis of 311 episodes. Enferm Infecc Microbiol Clin 17:56–64PubMed
20.
Zurück zum Zitat Sparrelid E, Hagglund H, Remberger M, Ringden O, Lonnqvist B, Ljungman P, Andersson J (1998) Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 22:795–800CrossRefPubMed Sparrelid E, Hagglund H, Remberger M, Ringden O, Lonnqvist B, Ljungman P, Andersson J (1998) Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 22:795–800CrossRefPubMed
21.
Zurück zum Zitat Steiner M, Villablanca J, Kersey J, Ramsay N, Haake R, Ferrieri P, Weisdorf D (1993) Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol 42:354–358PubMed Steiner M, Villablanca J, Kersey J, Ramsay N, Haake R, Ferrieri P, Weisdorf D (1993) Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol 42:354–358PubMed
22.
Zurück zum Zitat Talcott JA, Wingard JR (2003) Infectious syndromes in solid tumor therapy. In: Wingard JR, Bowden RA (eds) Management of infection in oncology patients. Martin Dunitz, London, pp 55–70 Talcott JA, Wingard JR (2003) Infectious syndromes in solid tumor therapy. In: Wingard JR, Bowden RA (eds) Management of infection in oncology patients. Martin Dunitz, London, pp 55–70
23.
Zurück zum Zitat Villablanca JG, Steiner M, Kersey J, Ramsay NK, Ferrieri P, Haake R, Weisdorf D (1990) The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant 5:387–393PubMed Villablanca JG, Steiner M, Kersey J, Ramsay NK, Ferrieri P, Haake R, Weisdorf D (1990) The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant 5:387–393PubMed
24.
Zurück zum Zitat Yoo JH, Huh DH, Choi JH, Shin WS, Kang MW, Kim CC, Kim DJ (1997) Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. Clin Infect Dis 25:1385–1391PubMed Yoo JH, Huh DH, Choi JH, Shin WS, Kang MW, Kim CC, Kim DJ (1997) Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. Clin Infect Dis 25:1385–1391PubMed
Metadaten
Titel
Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000
verfasst von
Mar Ortega
Montserrat Rovira
Manel Almela
Francesc Marco
Jorge Puig de la Bellacasa
José Antonio Martínez
Enric Carreras
Josep Mensa
Publikationsdatum
01.01.2005
Erschienen in
Annals of Hematology / Ausgabe 1/2005
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-004-0909-0

Weitere Artikel der Ausgabe 1/2005

Annals of Hematology 1/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.